D.A. Davidson & CO. Buys 103 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

D.A. Davidson & CO. increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 17.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 709 shares of the biopharmaceutical company’s stock after buying an additional 103 shares during the quarter. D.A. Davidson & CO.’s holdings in Regeneron Pharmaceuticals were worth $623,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $26,000. Fortitude Family Office LLC bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $31,000. MCF Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the last quarter. Criterion Capital Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $37,000. Finally, Bruce G. Allen Investments LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $40,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 22,830 shares of the firm’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the transaction, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, EVP Marion Mccourt sold 358 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $967.50, for a total value of $346,365.00. Following the sale, the executive vice president now directly owns 13,431 shares of the company’s stock, valued at $12,994,492.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Leonard S. Schleifer sold 22,830 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the completion of the transaction, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 54,071 shares of company stock valued at $52,812,907. Company insiders own 7.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on REGN shares. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. Truist Financial reiterated a “buy” rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Evercore ISI initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price objective on the stock. UBS Group upped their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Finally, TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $989.36.

View Our Latest Stock Report on REGN

Regeneron Pharmaceuticals Trading Down 1.2 %

NASDAQ:REGN opened at $973.16 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33. The stock’s fifty day moving average price is $945.50 and its two-hundred day moving average price is $918.05. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The company has a market cap of $107.23 billion, a P/E ratio of 28.75, a P/E/G ratio of 2.03 and a beta of 0.17.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The company had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.34 EPS for the current year.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Read More

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.